203 related articles for article (PubMed ID: 33728352)
21. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
22. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
[TBL] [Abstract][Full Text] [Related]
23. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
[TBL] [Abstract][Full Text] [Related]
24. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
[TBL] [Abstract][Full Text] [Related]
25. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
[TBL] [Abstract][Full Text] [Related]
26. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.
Tsukagoshi M; Araki K; Yokobori T; Altan B; Suzuki H; Kubo N; Watanabe A; Ishii N; Hosouchi Y; Nishiyama M; Shirabe K; Kuwano H
Oncotarget; 2017 Jun; 8(26):42159-42172. PubMed ID: 28178675
[TBL] [Abstract][Full Text] [Related]
28. CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.
Shi J; Guan X; Zhan F; Liu C; Li Z; Yao Y; Wang B; Lou C; Zhang Y
Cancer Biol Ther; 2019; 20(9):1290-1299. PubMed ID: 31311398
[TBL] [Abstract][Full Text] [Related]
29. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
[TBL] [Abstract][Full Text] [Related]
30. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
[TBL] [Abstract][Full Text] [Related]
31. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
Liu M; Qin Y; Hu Q; Liu W; Ji S; Xu W; Fan G; Ye Z; Zhang Z; Xu X; Yu X; Zhuo Q
Cancer Lett; 2021 Feb; 499():265-278. PubMed ID: 33232789
[TBL] [Abstract][Full Text] [Related]
32. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
[TBL] [Abstract][Full Text] [Related]
33. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.
Yan R; Li J; Zhou Y; Yao L; Sun R; Xu Y; Ge Y; An G
Life Sci; 2020 Jan; 241():117150. PubMed ID: 31837335
[TBL] [Abstract][Full Text] [Related]
35. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.
Ahmad G; Mackenzie GG; Egan J; Amiji MM
Mol Cancer Ther; 2019 Nov; 18(11):1961-1972. PubMed ID: 31439714
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Zhu X; Chen X; Li C; Zong G; Zhou G; Wan C
Hum Pathol; 2016 Nov; 57():182-192. PubMed ID: 27498060
[TBL] [Abstract][Full Text] [Related]
37. PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma.
Li C; Zhao Z; Zhou Z; Liu R
Dig Dis Sci; 2016 Mar; 61(3):767-73. PubMed ID: 26500118
[TBL] [Abstract][Full Text] [Related]
38. HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
Hu G; He N; Cai C; Cai F; Fan P; Zheng Z; Jin X
Pancreatology; 2019 Mar; 19(2):383-389. PubMed ID: 30670333
[TBL] [Abstract][Full Text] [Related]
39. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer.
Zhou Y; Jin X; Yu H; Qin G; Pan P; Zhao J; Chen T; Liang X; Sun Y; Wang B; Ren D; Zhu S; Wu H
Theranostics; 2022; 12(5):2080-2094. PubMed ID: 35265200
[No Abstract] [Full Text] [Related]
40. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.
Wan C; Gong C; Ji L; Liu X; Wang Y; Wang L; Shao M; Yang L; Fan S; Xiao Y; Wang X; Li M; Zhou G; Zhang Y
Mol Cell Biochem; 2015 Dec; 410(1-2):25-35. PubMed ID: 26276310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
